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Summary 
Background: Pharmacokinetic (PK)/pharmacodynamic (PD) modelling offers new insights 
to design protocols for sedation and analgesia in standing horses. 
Objectives: To evaluate the parameters and interactions between detomidine and methadone 
when given alone or combined in standing horses. 
Study design: Randomised, placebo-controlled, blinded, crossover. 
Methods: Eight adult healthy horses were given six treatments intravenously: saline (SAL); 
detomidine (5 µg/kg
 
bwt; DET); methadone (0.2 mg/kg
 
bwt; MET) alone or combined with 
detomidine [2.5 (MLD), 5 (MMD) or 10 (MHD) µg/kg
 
bwt]. Venous blood samples were 
obtained at predetermined times between 0 and 360 minutes after drug administration. 
Plasma detomidine and methadone were measured using a single, liquid/liquid extraction 
technique by liquid chromatography coupled with a triple quadrupole mass spectrometer 
(LC-MS/MS). Sequential PK/PD modelling compared rival models, with and without PK and 
PD interaction between drugs, to fit the PD data including height of the head above the 
ground (HHAG), a visual analogue scale for sedation (VAS), electrical (ET), thermal (TT) 
and mechanical (MT) nociceptive thresholds and gastrointestinal motility (GIM) [1].  
Results: Two and three compartment models best described the PK of detomidine and 
methadone, respectively. Detomidine decreased its own clearance as well as the clearance of 
methadone. The interaction of methadone on the effect of detomidine revealed an infra-
additive effect for HHAG (α = - 1.33), VAS (α = - 0.98) and GIM (α = - 1.05), a positive 
potentiation for ET (pot = 0.0041) and TT (pot = 0.133) and a synergistic to additive effect 
for MT (α = 0.78).  
 
Main limitations: This is a small experimental study.  
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Conclusions: Different PK/PD interactions were demonstrated for each PD parameter and 
could be modelled in vivo. The modelling of our data will allow us to simulate and predict the 
effect of constant rate infusions of both drugs for future investigations. 
 
Introduction 
Single intravenous (i.v.) combinations of α2 adrenoceptor agonists and opioids are commonly 
used in standing horses to provide or enhance sedation and analgesia. Detomidine has been 
extensively used in this way in combination with several different opioids [2-5] including 
methadone [2]. The pharmacodynamics (PD) of a number of i.v. combinations of detomidine 
with methadone were recently studied in order to identify a low dose combination that 
produces antinociception with minimal adverse effects [1]. 
 The pharmacokinetics (PK) of high i.v. doses of detomidine (30 µg/kg bwt) [6-8] and 
methadone at clinical doses (0.15 mg/kg bwt) [9] have been studied when administered 
separately. Sequential PK/PD modelling with nonlinear mixed effect models (NLME) is well 
established in the literature [10-12] and aims to report the relationship between concentration-
timecourse and effect of one or several drugs in a single model. This modelling approach is 
required to describe accurately what happens in terms of drug interaction. Furthermore, 
modelling allows simulation of an unobserved scenario, with other dose rates than those 
tested. In horses, these methods were used to model the PK and PD of detomidine 30 µg/kg 
bwt after i.v. or intramuscular administration [13]. Such PK/PD modelling of methadone in 
horses has not been reported, either alone or in combination with detomidine. Similarly, 
neither the PK nor any PK/PD modelling has been reported in horses after α2 adrenoceptor 
agonist-opioid combination administration in conscious horses.  
Therefore, the aim of the investigation was to develop a single analytical technique 
that would determine both detomidine and methadone in plasma samples, and model the PK 
and PD [1] data to characterise their interactions when given alone or in combination. An 
experimental study was designed to estimate the PK parameters in a six-period crossover 
including i.v. saline, detomidine (5 µg/kg bwt) alone and methadone (0.2 mg/kg bwt) alone, 
or combined with 2.5, 5 or 10 µg/kg bwt detomidine, and to model the interactions between 
their plasma concentration-timecourses and their PD effects [1].   
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Methods 
This investigation was designed as a randomised, placebo-controlled, observer-blinded, 
crossover study, with a washout period of at least one week between each of the six different 
treatments.   
 
Animals 
Plasma samples and PD data collected from the eight healthy adult crossbred horses studied 
by Gozalo-Marcilla et al. [1] were included in the study. They comprised four castrated males 
and four females aged 7 ± 2 years, weighing 372 ± 27 kg. A test of power of 80% and a 
significance level of 5% were used [1]. No sedatives or analgesics were administered for at 
least one month before the study.  
 
Drug administration 
After skin disinfection and subcutaneous injection of 1 ml 2% lidocaine
 
(Xylestesin 2%
a
), 
two 14 gauge i.v. catheters
 
were placed in the direction of the blood flow, one in the right 
jugular vein for drug administration (BD Angiocath 14 GA x 1.88
b
), and the other in the left 
jugular vein for blood sampling (G14 x 70 mm
c
). The final volume of injection was adjusted 
to 10 ml by adding saline and administered manually over 10 seconds at T0 by an assistant 
investigator (N.C.).  
In addition to saline control, five treatments were administered: 5 µg/kg bwt 
detomidine (Eqdomin 10 mg/ml
d
) (DET), 0.2 mg/kg bwt methadone (Mytedom 10 mg/ml
a
) 
alone (MET), or combined with 2.5 (MLD), 5 (MMD) or 10 (MHD) µg/kg bwt detomidine.   
Measurements and sample collection 
Pharmacodynamic variables (see below) were measured in triplicate by the main investigator 
(M.G.M.) at baseline before T0 and at 5, 15, 30, 45, 60, 75, 90, 120 and 180 min [1]. The 
main investigator was unaware of the identity of the treatment. Blood samples were taken by 
the assistant investigator 3 min before T0 and at 3, 5, 15, 30, 45, 60, 75, 90, 120, 180, 240, 
300 and 360 min after drug administration. Blood was withdrawn at each time point 
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immediately after assessment of sedation and cardiovascular evaluation and before 
nociceptive threshold testing and gastrointestinal data collection [1].  
Prior to drawing each 10 ml blood sample, another 10 ml of blood were discarded 
from the left jugular catheter. After each blood sampling, the catheter was flushed with 10 ml 
of a dilute heparinised saline solution (10 IU/ml). Blood samples were collected into 
heparinised blood tubes, labelled with the horse’s identification number and the sample time 
point and stored at 4 degrees Celsius (°C) for a maximum of 90 min before centrifugation at 
1330 g (Combate centrifuge
e
). The plasma was then transferred into previously labelled 
storage cryovials and stored at -70°C until PK analysis. 
Sample preparation 
Before sample preparation for PK analysis, plasma from the horses in the saline treatment 
group was used to validate a single method for quantification of both detomidine and 
methadone, which is described below.  
A volume of 290 µl of thawed plasma was combined with 10 µl of the internal 
standard (IS) fentanyl (30 ng/ml) in an Eppendorf Safe-Lock tube. A liquid/liquid extraction 
technique was employed by using 1 ml of ethyl acetate. After mixing for 15 min in a rotary 
shaker at 1000 rpm (rotary shaker AV-2
f
), the sample was centrifuged for 10 min at 11180 g 
at 4°C (M-240R centrifugeg). Later, 800 µl of the supernatant were transferred into another 
Eppendorf Safe-Lock tube and evaporated for 40 min at 30°C (RVC 2-18 speed-vacuumh). 
The samples were immediately reconstituted in 100 µl of the liquid chromatography mobile 
phase, mixed for 1 min (rotary shaker AV-2
f
) and centrifuged for 5 min at 11180 g at 4°C. 
Finally, 80 µl of the supernatant were transferred to a new vial.  
Determination of detomidine and methadone concentrations 
The samples were analysed by liquid chromatography
i
 coupled with a triple quadrupole mass 
spectrometer (Applied Biosystems/Sciex API 3200
j
) (LC-MS/MS). Chromatographic 
separation was achieved on a C18 column (C18 Kinetex 100 x 2.1 mm; 2.6 µm
k
) with a pre-
column of the same material, maintained at 40°C, with eluent A (ammonium acetate 5 mM + 
acetic acid 0.1%) and eluent B (acetonitrile + acetic acid 0.1%), used in a gradient mode 
(Supplementary Item 1). The volume of injection was 4 µl and the flow rate 0.3 ml/min. 
Retention times for detomidine, IS and methadone were 1.6, 2.8 and 3.9 min, respectively. 
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The MS was operated in the positive ion and multiple reaction monitoring (MRM) mode for 
the transitions 187→81 (detomidine), 310→105 (methadone) and 337→105 (fentanyl). 
Lower limits of quantification (LLOQ) were 0.10 and 0.05 ng/ml for detomidine and 
methadone, respectively.  
 
Pharmacokinetic analysis 
The plasma concentrations of both drugs at each time point were analysed with NLME using 
compartmental modelling with a physiologically relevant parametrisation (Phoenix 8.0
l
). 
Plasma concentration time curves for each drug were explored using one, two and 
three compartment models, defined by the clearance (Cl) and volumes of distribution for the 
central (V1) and peripheral compartments (V2, V3). For each PK parameter, individual values 
are modelled as functions of population typical value (tv) and individual random deviations 
Eta (η). Distributions for V and Cl for each drug for each compartment were fitted according 
to a log normal distributions, where for the i
th
 individual, Vi = tvV * exp (ηVi) and Cli = tvCl * 
exp (ηCli), respectively, with η following a normal distribution centred on 0 and with a 
variance ω2. A parsimonius selection method to justify the progressive inclusion of additional 
random effects was used to ensure the individual parameters were identifiable. Secondary 
parameters including volume of distribution at steady state (Vdss) and half lifes (t1/2α, t1/2β, 
t1/2ɣ) were calculated as secondary parameters in Phoenix
l
.  
The plasma concentration-time curves were initially fitted individually for each drug 
before modelling the two PK datasets together. Preliminary non-compartmental analysis 
(Phoenix 8.0
l
) revealed non-linearity in the detomidine PK (supra proportional increase in the 
area under the curve as the dose increases) and that detomidine significantly reduced the Cl 
of methadone. According to our hypothesis, we added a function to encode the modulation of 
detomidine and methadone Cl by detomidine in the PK model (proportionally to the 
concentration or the log of the concentration of detomidine).  
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Pharmacodynamic data  
The following data, as reported by Gozalo Marcilla et al. [1], were included in the PD model: 
height of the head above the ground (HHAG, cm), the visual analogue scale for sedation 
(VAS, 0 to 10 score, 0 no sedation neither ataxia, 10 maximal sedation and ataxia), 
nociceptive thresholds for electrical [ET, cut-out 20 Volts (V)], thermal (TT, cut-out 60ºC) 
and mechanical [MT, cut-out 20 Newtons (N)] stimuli, and gastrointestinal motility (GIM, 0 
to 20 score, 0 no intestinal sounds in any of the four abdominal quadrants, 20 long, loud, 
gurgling sounds, with a frequency of more than four sounds per min). 
 
Pharmacokinetic/pharmacodynamic model selection criteria  
Sequential PK/PD modelling (after freezing the PK parameters), was used to compare 
suitability of rival PK/PD models, with and without PD interaction between drugs, for fitting 
the PD data and estimating negative hysteresis. The plots were evaluated visually to 
determine the best model; these featured the observed data versus individual and population 
predictions, individual and population weighted residuals versus time and conditional 
weighted residuals versus time. The value of the Objective Function (OVF = -2 Log 
likelihood) and the Akaike Information Criterion (AIC) [14] were also used for model 
selection. Finally, visual predictive checks (VPCs) compared (by estimation of overlap) the 
20
th
, 50
th
 (median) and 80
th
 percentile predictions generated by the models to the distribution 
of the observed data.  
 Negative hysteresis (delay between plasma concentration and effect) was modelled 
with an effect compartment model. The link between the predicted plasma concentrations 
(Cp) and the effect compartment concentration (Ce) was given by the equation 1:  
 
   
   
                 (1)  
with ke0 being the transfer rate constant between the central compartment and the effect 
compartment (1/h). Pharmacodynamic endpoints were modelled independently from each 
other, therefore each candidate PK/PD model included two residual proportional error terms 
for PK (one per drug) and one additional error for the PD fitting. Only plasma concentrations 
equal to or above the LLOQ for the assays were included in the analysis. 
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Results  
All the animals tolerated the experiments and the study was conducted without 
complications. Only one horse became deeply sedated when receiving both drugs, alone or in 
combination [1].  
 
Pharmacokinetics 
The LC-MS/MS method for quantification of detomidine and methadone was validated 
according to the Guideline on bioanalytical method validation [15]. All validation data 
(precision, accuracy and stability) are reported in Supplementary Item 2. 
The plasma concentration-time curves for the two drugs are shown in Figs 1a and 1b. 
A two-compartment model with linear interaction best described the PK of detomidine (Figs 
1 and 2). Detomidine decreased its own Cl in a concentration-dependent fashion (decreased 
OVF: 204). The maximal detomidine body Cl was 2.63 l/kg bwt/h and it was reduced by the 
product of the coefficient of moderation of detomidine Cl (called S = 0.049) and the plasma 
concentration of detomidine. For illustration, this effect decreased Cl by 3.8, 1.5, 1% at 30 
min, 1 and 2 hours, respectively after administration of MMD. Pharmacokinetic values for 
both drugs are shown in Table 1.  
A three-compartment model best fitted the PK of methadone (Figs 1 and 2). Inclusion 
of a detomidine concentration-dependent effect on methadone Cl significantly improved the 
fit. The methadone Cl was 0.49 l/kg bwt/h and was reduced by the product of a coefficient 
describing the moderation of methadone Cl by detomidine (p = 0.063) and the detomidine 
plasma concentrations (e.g. 24, 2.0, 1.1% reductions at 30 minutes, 1 and 2 hours, 
respectively after administration of MMD). 
 
Pharmacokinetic-pharmacodynamic modelling  
Individual PK parameters (typical values tv and individual random deviations Eta η) of the 
best PK model were fixed to estimate the PD values in a sequential PK/PD modelling 
process. Seven rival PD models were compared to identify the best relationship between the 
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plasma concentrations and their potential interactions with the evaluated PD values. These 
models included the effect of one or both drugs and are shown in Supplementary Item 3. 
The terms used to describe the PD interactions are the following, depending if 
methadone has its own effect (alone) in the final model (then the interaction is either 
synergism, additivity or infra-additivity/antagonism), or not (positive of negative 
potentiation). 
-Additivity, i.e. 1 + 1 = 2, the effects of the two drugs in one PD parameter are the 
same as the sum of the individual effects; as Borrat et al. [16] with α = 0. 
-Synergism, i.e. 1 + 1 > 2, the effects of the two drugs in one PD parameter are more 
than additive; as Borrat et al. [16] with α > 0. 
-Infra-additivity (or partial antagonism), i.e. 1 + 1 < 2: the effect of one drug is 
decreased or suppressed by another drug; as Borrat et al. [16] with α < 0. 
-Positive potentiation, i.e. 1 + 0 > 1, the effect of one drug is increased by the 
administration of another drug itself without effect; pot > 1. 
The parameters for the PD variables are shown in Table 2.  Overall PK and PD results 
are summarised in Tables 3 and 4. 
The VPC plots for HHAG, VAS, ET, TT, MT and GIM are shown in Figures 3a, 3b, 
3c, 3d, 3e and 3f, respectively.  
 
Discussion 
This investigation makes an important contribution to clinical equine science by using PK/PD 
modelling data to describe the in vivo interaction between two drugs at six different 
endpoints. Equine plasma samples were analysed with an improved PK analytical method 
designed to measure concentrations of both α2-agonists and opioids simultaneously, reducing 
extraction times and costs dramatically. This single method for determination of both drugs 
was developed from previous studies of detomidine [6-8,13] and methadone [9,18]. As also 
reported by Knych et al. [8] and Grimsrud et al. [13], a two-compartment model best 
described the PK of detomidine in equine plasma in our study. However, for methadone, a 
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three-compartment model was used to describe its behaviour in contrast to previous reports of 
a two-compartmental best fit [9,18]. The PK data evaluation demonstrated detomidine’s 
inhibitory effect on methadone’s and on its own Cl, in agreement with observations on 
dexmedetomidine in humans [19] and cats [20]. In those studies, the α2 agonist reduced in its 
own drug elimination Cl directly proportional to the effects on cardiac output. This 
relationship cannot be confirmed in our study as the protocol was not intended to evaluate the 
cardiopulmonary effects, so cardiac output was not measured. 
The second impact of our methodology relates to refinement of the modelling phases. 
The PD data collected by Gozalo-Marcilla et al. [1] are measures of sedation (HHAG and 
VAS), antinociception (increased ET, TT and MT), and the side effect of intestinal 
hypomotility (GIM). These end-points are established representatives of the expected clinical 
effects ideally suited to PK/PD analysis. Our PK/PD modelling with NLME models allows 
information leverage and pooling from different periods of the study to identify shared PK 
and PD parameters [21]. Moreover, it enabled missing values and inconsistencies of the 
dataset to be managed. For example, one of the horses was profoundly sedated by both drugs, 
either alone or in combination [1]; but this was consistent with his abnormal PK.   
The simultaneous use of sedatives and analgesics is common practice in veterinary 
medicine, and it is generally assumed that drugs are additive. However, this may not always 
be the case, depending on different PD variables and physiological responses. In horses, it is 
widely accepted that combinations of opioids with α2 agonists enhance the sedative and 
analgesic properties of the latter [2,4,5]. Previously, no studies have explored the potential 
interactions between these agents in detail, expressed by empirical models using PD effects 
and plasma concentrations. The complex models for synergism [16,17] and potentiation 
allowed extraction of as much information as possible from our data collected from a small 
sample of the population, including evaluation of between-drug interaction. Future research 
using similar study designs would benefit from the same approach. 
An infra-additive synergism (or partial antagonism) was demonstrated for both 
measures of sedation, HHAG and VAS. With detomidine alone, HHAG was reduced, 
whereas methadone had a minimal or no effect on its own. However, the combination of 
methadone with detomidine partially reversed the detomidine-induced reduction in HHAG 
[1] due to this infra-additive synergism (higher HAAG values). Opioids may produce 
excitement and increased locomotor activity, especially at high doses [22]. At clinical doses, 
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Oliveira et al. [23] reported that the chin-to-floor distance decreased for 30 min after i.v. 
detomidine alone (10 µg/kg bwt) or combined with methadone (0.2 mg/kg bwt), but with the 
combination treatment the horses’ heads were higher for the first 5 min. Oliveira et al.’s 
conclusion that “methadone did not produce a synergic or additive sedative effect when 
combined with detomidine” is consistent with our results, indicating that this interaction can 
be defined as a negative potentiation [23]. A similar reasoning applies to the subjective 
measurement of sedation, VAS.  
A number of interactions were detected by evaluation of the antinociceptive effects: 
synergism to additivity was demonstrated with MT, whereas ET and TT showed potentiation. 
According to this analysis, methadone itself did not produce any electrical or thermal 
antinociception, but it potentiated the effects of detomidine [1]. The model indicated that 
methadone alone produced limited mechanical antinociception (none in some individuals). 
This may be a result of the different fibres activated by the stimuli employed (i.e. electrical -
nociceptive Aδ and C, and the Aβ not directly involved in antinociception; thermal - mainly 
C fibres; mechanical - both Aδ and C) [24]. This demonstrates the importance of using more 
than one stimulus when performing antinociceptive studies in standing horses [25]; agents 
from dissimilar drug groups, such as α2 agonists and opioids, may have different mechanisms 
of action.    
For GIM, the drug combination produced an infra-additive effect. It is well known 
that α2 agonists [26,27] and opioids [22,28] decrease intestinal motility. Although detomidine 
and methadone both have this effect when administered alone, it was not additive according 
to the model that best fitted the GIM data. Indeed, as demonstrated by Gozalo-Marcilla et al. 
[1], addition of 0.2 mg/kg bwt methadone to 5 µg/kg bwt detomidine (MMD) did not change 
the GIM scores recorded after detomidine alone (DET, 5 µg/kg bwt). 
 
All the models predicted the behaviour of the various parameters for all treatments 
with the exception of MLD. With MLD, the PK model tended to overestimate detomidine 
concentrations and therefore the sequential PK/PD modelling overestimated the effect of 
MLD for some of the endpoints. This may be explained by the minimal, short-term effects 
produced by this combination. It could be argued that a lower LLOQ than 0.10 ng/ml
 
should 
have been used, in order to detect detomidine concentrations for longer, as reported by 
Grimsrud et al. [6] and Knych et al. (2012) [8]. A lower LLOQ would probably have allowed 
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better modelling for this treatment (MLD). However, this is of limited importance as this 
combination produced no sedation and minimal antinociception [1], making MLD of limited 
clinical value.  
 The main advantage of using sequential PK/PD modelling is the ability to simulate the 
effect of different dosage regimens in order to find the optimal one to be tested under 
experimental circumstances. For example, with our data, we were able to simulate different 
protocols of combined i.v. boli and constant rate infusions (Supplementary Item 4) for the 
design of our next experimental study [29] before using these optimised protocols in a 
clinical study. However, we can only simulate within the range of doses tested and the 
associated plasma concentrations; modelling outside those ranges may lead to false 
predictions and misleading conclusions. A second limitation is the absence of different doses 
of methadone. Inclusion of more than one dose would have allowed more detailed study of 
the drug interactions. Nevertheless, it would have been technically challenging to perform a 
nine or sixteen period crossover study with four doses of both detomidine and methadone. A 
final limitation refers to the analytical method for methadone, as it was not enantiomer-
selective. Reported concentrations correspond to levo- and dex-methadone. Consequently, 
PK/PD modelling was performed assuming the same potency for both enantiomers.  
 In conclusion, this study demonstrates the optimal use of PK/PD data from a six-
period crossover study for estimating the PD and the interaction parameters for six different 
endpoints. It describes the PK and PD interactions of detomidine and methadone when given 
alone or in combination, which are different for each PD parameter: negative potentiation for 
HHAG, positive potentiation for TT and ET, infra-aditivity for VAS and GIM and synergism 
for MT. The resulting model will be used to predict the effect of constant rate infusions of 
both drugs in planning future investigations.  
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  Detomidine  Methadone 
Parameter Unit Estimate ηshk IIV%  Estimate ηshk IIV% 
tvCl1 l/kg bwt/h 2.63 6% 1.9  0.490 3% 2.8 
tvCl2 l/kg bwt/h 0.953 - -  3.16 - - 
tvCl3 l/kg bwt/h     0.249 - - 
tvV1 l/kg   0.618 - -  0.102 - - 
tvV2 l/kg   0.724 - -  0.310 11% 5.9 
tvV3 l/kg     0.218 9% 30.3 
tvS l/µg 0.049 28% 2.9     
tvp l/µg     0.063 22% 11.7 
r.e. PK  38%    26%   
vdss l/kg   1.34    0.77   
t1/2 α h 0.11    0.02   
t1/2 β h 0.71    0.38   
t1/2 ɣ h     1.62   
Table 1: Typical values (tv) and Inter Individual Variability (IIV) of pharmacokinetic 
parameters of detomidine and methadone in 8 standing horses following 5 treatments 
administered intravenously: 0.2 mg/kg bwt methadone (MET), 5 µg/kg bwt detomidine alone 
(DET), or 0.2 mg/kg bwt methadone combined with 10 (MHD), 5 (MMD) or 2.5 (MLD) 
µg/kg bwt detomidine. The reported parameters included clearance (Cl), volumes of 
distribution for the central (V1) and peripheral compartments (V2, V3), S: coefficient of 
moderation of detomidine clearance by detomidine, p: coefficient of moderation of 
methadone clearance by detomidine.  ηshk: eta shrinkage (%), the parameters’ IIV% is only 
reported when shrinkage is acceptable (<30%), i.e when there is enough data to identify 
individual parameters. r.e.PK: residual error of the PK model, vdss: volume of distribution at 
steady state, and t1/2: distribution or elimination half-lives. Omega is the variance of the PK 
parameters. 
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HHAG (cms) 
 
 VAS (0 – 10 score) 
 
 MT (Newtons) 
 
 TT (°Celsius) 
 
 ET (Volts) 
 
 GIM (0 – 20 score) 
Parameter Units Est. ηshk IIV%  Est. ηshk IIV%  Est.  ηshk IIV%  Est. ηshk IIV%  Est.  ηshk IIV%  Est.  ηshk IIV% 
tvKe0_DET 1/h 5.3 - -  8.5 5% 15.9  8.6 3% 23.3  8.2 - -  8.6 12% 38.1  5.6 - - 
tvKe0_MET 1/h 8.9 - -  3.2 - -  2.2 9% 133  39.5 - -  14.6 - -  8.9 - - 
                         
E0 (baseline) * 98.8 2% 0.28  0 - -  0.8 9% 59.1  44.0 3% 0.19  1.7 - -  14.7 - - 
tvImax combination * 1 (fixed)                  1 (fixed) 
tvIC50DET ng/ml 3.8 3% 46.0                  2.5 19% 3.5 
tvIC50MET ng/ml 846 - -                  1010 24% 31.4 
tvEmax combination * - - -  8.4 8% 1.7  19.1 - -          - - - 
tvEC50DET ng/ml - - -  2.39 4% 9.6  4.15 25% 1.4          - - - 
tvEC50MET ng/ml - - -  421 10% 9.6  401 13% 12.1          - - - 
tvn_DET - 1.36 9% 21.1  1.89 - -  15.5 - -          2.07 8% 21.8 
tvn_MET - 6.6 8% 23.7  18.2 7% 13.9  2.2 - -          0.89 11% 34.3 
α (synergism) - -1.33 10% 15.2  -0.98 21% 6.0  0.78 11% 251          -1.05 24% 22.9 
Borrat model type:  Infra-additive  Infra-additive  Synergistic/Additive          Infra-additive 
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Potentiation model:              [Methadone]   log [Methadone]     
tvEmax DET alone *             10.0 - -  3.1 18% 56.8     
tvEC50DET ng/ml             2.1 16% 9.0  3.9 7% 69.3     
tvn_DET -             1.94 20% 13.1  2.38 26% 14.9     
pot (potentiation) ml/ng             0.133   0.0041 20% 130     
r.ePD * 6.97  0.49  1.91  3.28  0.74  1.51 
 
Table 2: Pharmacokinetic/pharmacodynamic parameters of detomidine and methadone in 8 standing horses following 5 treatments administered 
intravenously: 0.2 mg/kg bwt methadone (MET), 5 µg/kg bwt detomidine alone (DET), or 0.2 mg/kg bwt methadone combined with 10 (MHD), 
5 (MMD) or 2.5 (MLD) µg/kg bwt detomidine. Pharmacodynamic variables include the height of the head above the ground (HHAG), 
gastrointestinal motility (GIM), the visual analogue scale (VAS), and antinociceptive thresholds with mechanical (MT), thermal (TT) and 
electrical (ET) stimuli. T HHAG, VAS and GIM best fitted infra-addition (1 + 1 < 2), whereas MT better synergism (1 + 1 > 2), both using the 
model from Borrat et al. [16]. The TT and ET best fitted an empirical positive potentiation model (1 + 0 > 1). tvKe0_DET is the typical value 
used to predict the dose-concentration relationship and the course of the effect of detomidine, tvKe0_MET is the typical value used to predict the 
dose-concentration relationship and the course of the effect of methadone, E0 is the response at baseline. tvImax combination is the typical value 
of the maximal response of the combination of drugs, tvIC50DET is the typical value of the effect site concentration eliciting a response equal to 
half of the baseline response with detomidine, tvIC50MET is the typical value of the effect site concentration eliciting a response equal to half of 
the baseline response with methadone, tvEmax combination is the typical value of the maximal effect of the combination of drugs, tvEC50DET 
is the typical value of the effect site concentration eliciting a response equal to half of E0 with detomidine, tvEC50MET is the typical value of 
the effect site concentration eliciting a response equal to half of E0 with methadone, tvn_DET is the typical value for n which determines 
steepness of the curve of the parameter versus Ce methadone curve, α (synergism) is the interaction parameter, tvEmax DET alone is the typical 
value of the maximal effect of detomidine alone, tvn_MET is the typical value for n which determines steepness of the curve of the parameter 
versus the predicted effect site concentration (Ce) methadone curve, pot (potentiation) is the potentiation parameter. ηshk: eta shrinkage (%), the 
parameters’ IIV% is only reported when shrinkage is acceptable (<30%), i.e when there is enough data to identify individual parameters. r.e.PD : 
residual error for each PD endpoint.  
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* unit depends on PD endpoint, HHAG (cms), VAS (0 – 10 score), MT (Newtons), TT (°Celsius), ET (Volts), GIM (0 – 20 score); IIV %: 
interindividual variability (expressed as a percentage coefficient of variation). 
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Effect of  
 
Parameter 
affected 
Overall effect 
 
Comment 
 
Plasma detomidine 
concentration 
 
 
Detomidine 
clearance 
 
 
Decrease 
 
 
 
Detomidine inhibits its own 
clearance (supposedly through 
reduction of cardiac ouput) 
 
Plasma detomidine 
concentration 
 
Methadone 
clearance 
 
Small decrease 
 
 
Detomidine inhibits methadone´s 
clearance (supposedly through 
reduction of cardiac ouput) 
 
Table 3: Summarised pharmacokinetic results of the effects of detomidine and methadone in 
8 standing horses following 5 treatments administered intravenously: 0.2 mg/kg bwt 
methadone (MET), 5 µg/kg bwt detomidine alone (DET), or 0.2 mg/kg bwt methadone 
combined with 10 (MHD), 5 (MMD) or 2.5 (MLD) µg/kg bwt detomidine. 
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Parameter 
 
Effect of 
detomidine 
alone 
Effect of 
methadone 
alone Effect of interaction Model 
 Value of 
interaction 
parameter 
HHAG (cms) ↓↓ = or ↓ 
Infra-additive 
(antagonism) 
 
                 
 
     
        
  
     
        
      
     
        
  
     
        
 
       
    
     
        
  
     
        
      
     
        
  
     
        
 
       
 
 
 
 
α = - 1.33 
VAS (0 – 10 
score) 
↑↑ ↑ 
Infra-additive 
(antagonism) 
 
 
              
 
     
        
  
     
        
      
     
        
  
     
        
 
       
    
     
        
  
     
        
      
     
        
  
     
        
 
       
 
 
 
α = - 0.98 
MT 
(Newtons) 
↑↑ ↑↑ 
Synergism 
              
 
     
        
  
     
        
      
     
        
  
     
        
 
       
    
     
        
  
     
        
      
     
        
  
     
        
 
       
 
 α = + 0.78 
TT (°Celsius) ↑↑ 
= 
 
Positive 
potentiation of 
detomidine by 
methadone 
                                    
     
 
                
    
 
pot = + 0.133 
ET (Volts) ↑↑ 
= 
 
Positive 
potentiation of 
detomidine by 
methadone 
                            
     
 
                
    
 
pot = +0.0041 
GIM (0 – 20 
score) 
 
↓↓ ↓↓ 
Infra-additive 
(antagonism) 
  
   
  
 
 
 
 
         
 
     
        
  
     
        
      
     
        
  
     
        
 
       
    
     
        
  
     
        
      
     
        
  
     
        
 
       
  
 
 
 
 
α = - 1.05 
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Table 4: Summarised pharmacodynamic results of the effects of detomidine and methadone in 8 standing horses following 5 treatments 
administered intravenously: 0.2 mg/kg bwt methadone (MET), 5 µg/kg bwt detomidine alone (DET), or 0.2 mg/kg bwt methadone combined 
with 10 (MHD), 5 (MMD) or 2.5 (MLD) µg/kg bwt detomidine. 
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